Nuria Perez-Diaz-Del-Campo, Gabriele Castelnuovo, Arianna Ferro, Gian Paolo Caviglia, Chiara Rosso, Eleonora Dileo, Marta Guariglia, Angelo Armandi, Francesca Saba, Giorgio Maria Saracco, Federica Barutta, Guglielmo Beccuti, Gabriella Gruden, Zobair M Younossi, Elisabetta Bugianesi
{"title":"MASLD和相关合并症对MASLD- t2dm混合队列认知和健康相关生活质量的影响","authors":"Nuria Perez-Diaz-Del-Campo, Gabriele Castelnuovo, Arianna Ferro, Gian Paolo Caviglia, Chiara Rosso, Eleonora Dileo, Marta Guariglia, Angelo Armandi, Francesca Saba, Giorgio Maria Saracco, Federica Barutta, Guglielmo Beccuti, Gabriella Gruden, Zobair M Younossi, Elisabetta Bugianesi","doi":"10.14309/ajg.0000000000003594","DOIUrl":null,"url":null,"abstract":"<p><strong>Background aims: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) coexists with multiple comorbidities that contribute to impaired vascular function, worsening cognitive impairment, and quality of life. This study aimed to evaluate the impact of MASLD and related comorbidities on cognitive function and health-related quality of life (HRQoL).</p><p><strong>Methods: </strong>A total of 601 overweight/obese patients with MASLD and/or Type 2 Diabetes Mellitus were included. Liver stiffness (LS) measurement and steatosis were assessed by transient elastography and controlled attenuation parameter (CAP), respectively. Cognitive function and HRQoL were evaluated using the RBANS and SF-36 questionnaires.</p><p><strong>Results: </strong>MASLD-related comorbidities were found to significantly and clinically affect cognitive function and HRQoL. Patients with severe steatosis (CAP≥300 dB/m, n=378) exhibited median cognitive scores falling into the abnormal range (p=0.056), with statistically significant lower scores in physical functioning (p<0.001), vitality (p=0.011), general health (p=0.001), and immediate memory (p=0.034), as well as a trend toward lower visuospatial/construction scores (p=0.058) than CAP<300 dB/m. Among patients with significant or high LS (LS≥8 kPa, n=69), lower physical functioning (p<0.001), higher limitations physical (p=0.004), and worse general health (p=0.011) were observed compared to those with LS<8 kPa. In the multivariate adjusted analyses, CAP≥300 dB/m was significantly associated with cognitive impairment (OR:1.42, 95% CI 1.0; 2.0, p=0.045), whereas LS≥8 kPa was associated with higher limitations physical (OR:1.9, 95% CI 1.1; 3.2, p=0.019).</p><p><strong>Conclusions: </strong>Our findings highlight the relationship between MASLD severity and impairment in cognitive function and HRQoL, underscoring its multifactorial nature. Specifically, severe hepatic steatosis may be a risk factor for cognitive decline, whereas significant or high liver stiffness appears to have a greater impact on HRQoL.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.0000,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of MASLD and associated comorbidities on Cognitive and Health-related Quality of Life outcomes in a Mixed MASLD-T2DM Cohort.\",\"authors\":\"Nuria Perez-Diaz-Del-Campo, Gabriele Castelnuovo, Arianna Ferro, Gian Paolo Caviglia, Chiara Rosso, Eleonora Dileo, Marta Guariglia, Angelo Armandi, Francesca Saba, Giorgio Maria Saracco, Federica Barutta, Guglielmo Beccuti, Gabriella Gruden, Zobair M Younossi, Elisabetta Bugianesi\",\"doi\":\"10.14309/ajg.0000000000003594\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background aims: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) coexists with multiple comorbidities that contribute to impaired vascular function, worsening cognitive impairment, and quality of life. This study aimed to evaluate the impact of MASLD and related comorbidities on cognitive function and health-related quality of life (HRQoL).</p><p><strong>Methods: </strong>A total of 601 overweight/obese patients with MASLD and/or Type 2 Diabetes Mellitus were included. Liver stiffness (LS) measurement and steatosis were assessed by transient elastography and controlled attenuation parameter (CAP), respectively. Cognitive function and HRQoL were evaluated using the RBANS and SF-36 questionnaires.</p><p><strong>Results: </strong>MASLD-related comorbidities were found to significantly and clinically affect cognitive function and HRQoL. Patients with severe steatosis (CAP≥300 dB/m, n=378) exhibited median cognitive scores falling into the abnormal range (p=0.056), with statistically significant lower scores in physical functioning (p<0.001), vitality (p=0.011), general health (p=0.001), and immediate memory (p=0.034), as well as a trend toward lower visuospatial/construction scores (p=0.058) than CAP<300 dB/m. Among patients with significant or high LS (LS≥8 kPa, n=69), lower physical functioning (p<0.001), higher limitations physical (p=0.004), and worse general health (p=0.011) were observed compared to those with LS<8 kPa. In the multivariate adjusted analyses, CAP≥300 dB/m was significantly associated with cognitive impairment (OR:1.42, 95% CI 1.0; 2.0, p=0.045), whereas LS≥8 kPa was associated with higher limitations physical (OR:1.9, 95% CI 1.1; 3.2, p=0.019).</p><p><strong>Conclusions: </strong>Our findings highlight the relationship between MASLD severity and impairment in cognitive function and HRQoL, underscoring its multifactorial nature. Specifically, severe hepatic steatosis may be a risk factor for cognitive decline, whereas significant or high liver stiffness appears to have a greater impact on HRQoL.</p>\",\"PeriodicalId\":7608,\"journal\":{\"name\":\"American Journal of Gastroenterology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":8.0000,\"publicationDate\":\"2025-06-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.14309/ajg.0000000000003594\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ajg.0000000000003594","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Impact of MASLD and associated comorbidities on Cognitive and Health-related Quality of Life outcomes in a Mixed MASLD-T2DM Cohort.
Background aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) coexists with multiple comorbidities that contribute to impaired vascular function, worsening cognitive impairment, and quality of life. This study aimed to evaluate the impact of MASLD and related comorbidities on cognitive function and health-related quality of life (HRQoL).
Methods: A total of 601 overweight/obese patients with MASLD and/or Type 2 Diabetes Mellitus were included. Liver stiffness (LS) measurement and steatosis were assessed by transient elastography and controlled attenuation parameter (CAP), respectively. Cognitive function and HRQoL were evaluated using the RBANS and SF-36 questionnaires.
Results: MASLD-related comorbidities were found to significantly and clinically affect cognitive function and HRQoL. Patients with severe steatosis (CAP≥300 dB/m, n=378) exhibited median cognitive scores falling into the abnormal range (p=0.056), with statistically significant lower scores in physical functioning (p<0.001), vitality (p=0.011), general health (p=0.001), and immediate memory (p=0.034), as well as a trend toward lower visuospatial/construction scores (p=0.058) than CAP<300 dB/m. Among patients with significant or high LS (LS≥8 kPa, n=69), lower physical functioning (p<0.001), higher limitations physical (p=0.004), and worse general health (p=0.011) were observed compared to those with LS<8 kPa. In the multivariate adjusted analyses, CAP≥300 dB/m was significantly associated with cognitive impairment (OR:1.42, 95% CI 1.0; 2.0, p=0.045), whereas LS≥8 kPa was associated with higher limitations physical (OR:1.9, 95% CI 1.1; 3.2, p=0.019).
Conclusions: Our findings highlight the relationship between MASLD severity and impairment in cognitive function and HRQoL, underscoring its multifactorial nature. Specifically, severe hepatic steatosis may be a risk factor for cognitive decline, whereas significant or high liver stiffness appears to have a greater impact on HRQoL.
期刊介绍:
Published on behalf of the American College of Gastroenterology (ACG), The American Journal of Gastroenterology (AJG) stands as the foremost clinical journal in the fields of gastroenterology and hepatology. AJG offers practical and professional support to clinicians addressing the most prevalent gastroenterological disorders in patients.